Nath Bio-Genes (India) Ltd
NSE: NATHBIOGEN BSE: 537291
Incorporated in 1993, Nath Bio-Genes Ltd is in the business of Production, Processing, and Marketing of Hybrid and GM Seeds[1]
₹158
52W: ₹126 — ₹239
PE 7.74 · Book ₹363 · -56% vs bookMarket Cap₹301 Cr
Stock P/E7.74Price to Earnings
ROCE7.18%Return on Capital
ROE5.83%Return on Equity
Div. Yield1.24%Face Value ₹10
Strengths
- +Stock is trading at 0.41 times its book value
- +Debtor days have improved from 111 to 70.9 days.
Weaknesses
- −Tax rate seems low
- −Company has a low return on equity of 6.27% over last 3 years.
- −Contingent liabilities of Rs.89.3 Cr.
- −Dividend payout has been low at 9.01% of profits over last 3 years
Shareholding Pattern
Promoters45.59%
FIIs0.22%
DIIs0.01%
Public54.17%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% |
| FIIs | 0.21% | 0.18%▼0.0 | 0.19%▲0.0 | 0.21%▲0.0 | 0.41%▲0.2 | 0.32%▼0.1 | 0.31%▼0.0 | 0.22%▼0.1 |
| DIIs | 4.37% | 4.37% | 4.37% | 3.94%▼0.4 | 2.25%▼1.7 | 0.76%▼1.5 | 0.01%▼0.8 | 0.01% |
| Public | 49.8% | 49.83%▲0.0 | 49.83% | 50.24%▲0.4 | 51.73%▲1.5 | 53.31%▲1.6 | 54.08%▲0.8 | 54.17%▲0.1 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 31.74 | 43.04 | 243.88 | 32.19 | 36.87 | 49.37 | 280.17 | 39.77 | 65.96 | 45.69 |
| Expenses | 25.96 | 38.57 | 206.82 | 25.63 | 29.36 | 46.2 | 241.27 | 32.58 | 57.12 | 39.07 |
| Operating Profit | 5.78 | 4.47 | 37.06 | 6.56 | 7.51 | 3.17 | 38.9 | 7.19 | 8.84 | 6.62 |
| OPM % | 18.21% | 10.39% | 15.2% | 20.38% | 20.37% | 6.42% | 13.88% | 18.08% | 13.4% | 14.49% |
| Net Profit | 3.96 | 3.21 | 33.89 | 2.89 | 2.66 | 4.71 | 38.21 | 4.2 | 7.23 | 3.79 |
| EPS ₹ | 2.08 | 1.69 | 17.83 | 1.52 | 1.4 | 2.48 | 20.11 | 2.21 | 3.8 | 1.99 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹432Cr, up 63% YoY. OPM at 12%.
Debt Position
Borrowings at ₹122Cr. Debt-to-equity ratio: 0.18x. Healthy balance sheet.
Institutional Flow
DIIs: 0.01% (-4.61pp change). FIIs: 0.22% (+0.15pp change). Promoters hold 45.59%.
Margin & Efficiency
ROCE declining from 26% (Mar 2015) to 7% (Mar 2026). Working capital days: 258.
Valuation
PE 7.74x with 7.18% ROCE. Price is -56% above book value of ₹363. Dividend yield: 1.24%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 11 May - Earning Call Transcript held on 05th May 2026
- NBIL Concall 11 May - Audio recording of 5 May 2026 conference call on audited Q4 and FY26 results uploaded.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 11 May - Company confirms it is not a large corporate as of 31 March 2026; outstanding long-term borrowing nil.
- Announcement under Regulation 30 (LODR)-Investor Presentation 4 May - Investor Presentation on Financial Results as on 31st March 2026
- Board Meeting Outcome for Outcome Of Board Meeting 4 May - FY26 audited results, Rs 2 dividend, independent director reappointed, MD pay raised to Rs 1.44 crore.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse